Antibody Response Dynamics to the Plasmodium Falciparum Conserved Vaccine Candidate Antigen, Merozoite Surface Protein-1 C-terminal 19kD (MSP1-19kD), in Peruvians Exposed to Hypoendemic Malaria Transmission

Overview

Journal Malar J

Publisher Biomed Central

Specialty Tropical Medicine

Date 2008 Sep 11

PMID 18782451

Citations 20

Authors

Katherine J Torres

Eva H Clark

Jean N Hernandez

Katherine E Soto-Cornejo

Dionicia Gamboa

OraLee H Branch

Affiliations

Soon will be listed here.

Abstract

Background: In high-transmission areas, developing immunity to symptomatic Plasmodium falciparum infections requires 2-10 years of uninterrupted exposure. Delayed malaria-immunity has been attributed to difficult-to-develop and then short-lived antibody responses.

Methods: In a study area with <0.5 P. falciparum infections/person/year, antibody responses to the MSP1-19kD antigen were evaluated and associations with P. falciparum infections in children and adults. In months surrounding and during the malaria seasons of 2003-2004, 1,772 participants received > or =6 active visits in one study-year. Community-wide surveys were conducted at the beginning and end of each malaria season, and weekly active visits were completed for randomly-selected individuals each month. There were 79 P. falciparum infections with serum samples collected during and approximately one month before and after infection. Anti-MSP1-19kD IgG levels were measured by ELISA.

Results: The infection prevalence during February-July was similar in children (0.02-0.12 infections/person/month) and adults (0.03-0.14 infections/person/month) and was negligible in the four-month dry season. In children and adults, the seroprevalence was maintained in the beginning (children = 28.9%, adults = 61.8%) versus ending malaria-season community survey (children = 26.7%, adults = 64.6%). Despite the four-month non-transmission season, the IgG levels in Plasmodium-negative adults were similar to P. falciparum-positive adults. Although children frequently responded upon infection, the transition from a negative/low level before infection to a high level during/after infection was slower in children. Adults and children IgG-positive before infection had reduced symptoms and parasite density.

Conclusion: Individuals in low transmission areas can rapidly develop and maintain alphaMSP1-19kD IgG responses for >4 months, unlike responses reported in high transmission study areas. A greater immune capacity might contribute to the frequent asymptomatic P. falciparum infections in this Peruvian population.

Citing Articles

Unravelling heterogeneous malaria transmission dynamics in the Peruvian Amazon: insights from a cross-sectional survey.

Pinedo-Cancino V, Arista K, Baldeviano G, Saavedra-Langer R, Arana A, Vasquez-Chasnamote M Malar J. 2024; 23(1):209.

PMID: 39010126 PMC: 11251108. DOI: 10.1186/s12936-024-05032-8.

Nutrient Deficiencies and Potential Alteration in Plasma Levels of Naturally Acquired Malaria-Specific Antibody Responses in Tanzanian Children.

Mbugi E, Den Hartog G, Veenemans J, Chilongola J, Verhoef H, Savelkoul H Front Nutr. 2022; 9:872710.

PMID: 35782946 PMC: 9247637. DOI: 10.3389/fnut.2022.872710.

Anti-MSP-10 IgG indicates recent exposure to Plasmodium vivax infection in the Peruvian Amazon.

Rosas-Aguirre A, Patra K, Calderon M, Torres K, Gamboa D, Arocutipa E JCI Insight. 2019; 5(1).

PMID: 31770108 PMC: 7030819. DOI: 10.1172/jci.insight.130769.

Evaluation of Plasmodium falciparum MSP10 and its development as a serological tool for the Peruvian Amazon region.

Bendezu J, Villasis E, Morales Ruiz S, Garro K, Infante B, Gutierrez-Loli R Malar J. 2019; 18(1):327.

PMID: 31547821 PMC: 6757379. DOI: 10.1186/s12936-019-2959-8.

Development of B Cell Memory in Malaria.

Ly A, Hansen D Front Immunol. 2019; 10:559.

PMID: 31001244 PMC: 6454213. DOI: 10.3389/fimmu.2019.00559.

References

Roberts D, LAUGHLIN L, Hsheih P, LEGTERS L . DDT, global strategies, and a malaria control crisis in South America. Emerg Infect Dis. 1997; 3(3):295-302. PMC: 2627649. DOI: 10.3201/eid0303.970305. View

Riley E, Morris-Jones S, Blackman M, Greenwood B, Holder A . A longitudinal study of naturally acquired cellular and humoral immune responses to a merozoite surface protein (MSP1) of Plasmodium falciparum in an area of seasonal malaria transmission. Parasite Immunol. 1993; 15(9):513-24. DOI: 10.1111/j.1365-3024.1993.tb00639.x. View

Malkin E, Long C, Stowers A, Zou L, Singh S, Macdonald N . Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. PLoS Clin Trials. 2007; 2(4):e12. PMC: 1847697. DOI: 10.1371/journal.pctr.0020012. View

Aramburu Guarda J, Ramal Asayag C, Witzig R . Malaria reemergence in the Peruvian Amazon region. Emerg Infect Dis. 1999; 5(2):209-15. PMC: 2640690. DOI: 10.3201/eid0502.990204. View

John C, ODonnell R, Sumba P, Moormann A, de Koning-Ward T, King C . Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J Immunol. 2004; 173(1):666-72. DOI: 10.4049/jimmunol.173.1.666. View

Diallo T, Spiegel A, Diouf A, Lochouarn L, Kaslow D, Tall A . Short report: differential evolution of immunoglobulin G1/G3 antibody responses to Plasmodium falciparum MSP1(19) over time in malaria-immune adult Senegalese patients. Am J Trop Med Hyg. 2002; 66(2):137-9. DOI: 10.4269/ajtmh.2002.66.137. View

Chitarra V, Holm I, Bentley G, Petres S, Longacre S . The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate. Mol Cell. 1999; 3(4):457-64. DOI: 10.1016/s1097-2765(00)80473-6. View

Branch O, Casapia W, Gamboa D, Hernandez J, Alava F, Roncal N . Clustered local transmission and asymptomatic Plasmodium falciparum and Plasmodium vivax malaria infections in a recently emerged, hypoendemic Peruvian Amazon community. Malar J. 2005; 4:27. PMC: 1190209. DOI: 10.1186/1475-2875-4-27. View

Fruh K, Doumbo O, Muller H, Koita O, McBride J, Crisanti A . Human antibody response to the major merozoite surface antigen of Plasmodium falciparum is strain specific and short-lived. Infect Immun. 1991; 59(4):1319-24. PMC: 257845. DOI: 10.1128/iai.59.4.1319-1324.1991. View

10.

Breman J, Alilio M, Mills A . Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg. 2004; 71(2 Suppl):1-15. View

11.

Singer L, Mirel L, Kuile F, Branch O, Vulule J, Kolczak M . The effects of varying exposure to malaria transmission on development of antimalarial antibody responses in preschool children. XVI. Asembo Bay Cohort Project. J Infect Dis. 2003; 187(11):1756-64. DOI: 10.1086/375241. View

12.

Braga E, Barros R, Reis T, Fontes C, Morais C, Martins M . Association of the IgG response to Plasmodium falciparum merozoite protein (C-terminal 19 kD) with clinical immunity to malaria in the Brazilian Amazon region. Am J Trop Med Hyg. 2002; 66(5):461-6. DOI: 10.4269/ajtmh.2002.66.461. View

13.

Mlambo G, Mutambu S, Mduluza T, Soko W, Mbedzi J, Chivenga J . Antibody responses to Plasmodium falciparum vaccine candidate antigens in three areas distinct with respect to altitude. Acta Trop. 2006; 100(1-2):70-8. DOI: 10.1016/j.actatropica.2006.09.012. View

14.

Wykes M, Good M . Memory B cell responses and malaria. Parasite Immunol. 2006; 28(1-2):31-4. DOI: 10.1111/j.1365-3024.2006.00768.x. View

15.

Tongren J, Drakeley C, McDonald S, Reyburn H, Manjurano A, Nkya W . Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. Infect Immun. 2005; 74(1):257-64. PMC: 1346665. DOI: 10.1128/IAI.74.1.257-264.2006. View

16.

Singh S, Miura K, Zhou H, Muratova O, Keegan B, Miles A . Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun. 2006; 74(8):4573-80. PMC: 1539572. DOI: 10.1128/IAI.01679-05. View

17.

Cavanagh D, Elhassan I, Roper C, Robinson V, Giha H, Holder A . A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. J Immunol. 1998; 161(1):347-59. View

18.

Roshanravan B, Kari E, Gilman R, Cabrera L, Lee E, Metcalfe J . Endemic malaria in the Peruvian Amazon region of Iquitos. Am J Trop Med Hyg. 2003; 69(1):45-52. View

19.

Snow R, CRAIG M, Deichmann U, Le Sueur D . A preliminary continental risk map for malaria mortality among African children. Parasitol Today. 1999; 15(3):99-104. DOI: 10.1016/s0169-4758(99)01395-2. View

20.

Chang S, Case S, Gosnell W, Hashimoto A, Kramer K, Tam L . A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immun. 1996; 64(1):253-61. PMC: 173753. DOI: 10.1128/iai.64.1.253-261.1996. View